UPCommons. Portal del coneixement obert de la UPC
Publicación
Artículo científico (JournalArticle)
Development of a ternary cyclodextrin–arginine–ciprofloxacin antimicrobial complex with enhanced stability
Designing useful functionalities in clinically validated, old antibiotics holds promise to provide the most economical solution for the global lack of effective antibiotics, as undoubtedly a serious health threat. Here we show that using the surface chemistry of the cyclodextrin (ßCD) cycle and arginine (arg) as a linker, provides more stable ternary antibiotic complex (ßCD-arg-cpx). In contrast to classical less stable inclusion complexes, which only modify antibiotic solubility, here-presented ternary complex is more stable and controls drug release. The components of the complex intensify interactions with bacterial membranes and increase the drug’s availability inside bacterial cells, thereby improving its antimicrobial efficacy and safety profile. Multifunctional antibiotics, formulated as drug delivery systems per se, that take the drug to the site of action, maximize its efficacy, and provide optical detectability are envisaged as the future in fighting against infections. Their role as a tool against multiresistant strains remains as interesting challenge open for further research., The authors are grateful to Angel Blanco Blanes and Dr. Samuel Sanchez from the Smart
Nano-Bio-Devices group at the Institute for Bioengineering of Catalonia for zeta
potential measurements as well as to Dr Dušan Žigon from Center for Mass Spectrometry at Jozef Stefan Institute for ToF MS analysis. The European Commission has
funded this work under Horizon 2020’s Marie Skłodowska-Curie Actions COFUND
scheme (Grant Agreement no. 712754) and by the Severo Ochoa program of the Spanish
Ministry of Science and Competitiveness (Grant SEV-2014-0425 (2015-2019)). E.T. was
supported by grants from the Spanish Ministerio de Economia y Competitividad
(MINECO/FEDER) (RTI2018-098573-B-100), Generalitat de Catalunya (2017SGR-1079
and CERCA program), the Catalan Cystic Fibrosis associations and the La Caixa
Foundation. Additional funding support has been provided to M.V. by grants from the
Slovenian Research Agency (ARRS) (grants J2-8169, N2-0150, and P2-0091)